Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Queensland Health
Accenture
Johnson and Johnson
Boehringer Ingelheim
Chubb
Colorcon
McKinsey
Fish and Richardson

Generated: April 25, 2018

DrugPatentWatch Database Preview

ZOFRAN Drug Profile

« Back to Dashboard

Which patents cover Zofran, and what generic alternatives are available?

Zofran is a drug marketed by Novartis Pharms Corp and Glaxosmithkline and is included in five NDAs.

The generic ingredient in ZOFRAN is ondansetron. There are twenty-eight drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
Drug patent expirations by year for ZOFRAN
Pharmacology for ZOFRAN
Medical Subject Heading (MeSH) Categories for ZOFRAN
Synonyms for ZOFRAN
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,4-Tetrahydro-9-methyl-3-(2-methyl-1H-imidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H- carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1 -yl)methyl]-4H-carbazol-4-one
1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one
1,2,3,9,-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
103639-04-9
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
39O049
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
9-Methyl-3- (2-methyl-imidazol-1ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-Methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-2,3-dihydro-1H-carbazol-4(9H)-one
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
9-methyl-3-[(2-methylimidazolyl)methyl]-1,2,3,9-tetrahydro-4aH-carbazol-4-one
99614-01-4
99614-01-4 (mono-hydrochloride)
99614-02-5
AB0013753
AB00373674
AB00373674_18
AB00373674_19
AB00373674-15
AB00373674-17
AB2000413
AC1L1IIM
ACN-049703
ACT02589
AK-29654
AKOS000599484
AKOS016340526
AN-6592
Apo-ondansetron
BAS 00717177
BBL010304
BC220610
BCP9001025
BDBM85330
BPBio1_001118
BR-29654
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CAS_68647
CAS-99614-02-5
CBDivE_008994
CHEBI:7773
CHEMBL46
CPD001307702
CS-2393
CTK8G2184
D00456
D0K7WK
DB00904
DESMETHYLONDANSETRON
DR001119
DSSTox_CID_3393
DSSTox_GSID_23393
DSSTox_RID_77011
DTXSID8023393
FELGMEQIXOGIFQ-UHFFFAOYSA-N
FT-0631004
GR 38032
GR 38032X
GR-38032
GR-38032F
GR-38032F/GR-38032
GR38032F
GTPL2290
HMS2090H16
HMS3259H08
HMS3371E18
HSDB 8304
HY-B0002B
I06-0687
I06-1329
I544
KB-308401
KS-00000JSZ
KS-5227
L000456
LS-172305
LS-51878
MCULE-9438746800
MFCD00833882
MLS006011928
MolPort-001-944-253
NC00706
NCGC00179341-02
NCGC00179341-04
NCI60_022780
Novo-ondansetron
NSC_68647
Odansetron [common misspelling of ondansetron]
ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron [USP:INN:BAN]
Ondansetron Injection
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PL042447
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
QC-660
Ratio-ondansetron
S-2116
s1996
SAM002589958
Sandoz ondansetron
SBB066158
SC-07554
SCHEMBL4542
SMR001307702
SN-307
SPBio_002938
ST077669
ST2412612
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
Tox21_113048
Tox21_113048_1
VA11441
Z1741971217
Zofran (TN)
ZOFRAN IN PLASTIC CONTAINER
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
Zuplenz

US Patents and Regulatory Information for ZOFRAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride INJECTABLE;INJECTION 020007-001 Jan 4, 1991 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-001 Jan 27, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-002 Jan 27, 1999 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ZOFRAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-001 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride SOLUTION;ORAL 020605-001 Jan 24, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride INJECTABLE;INJECTION 020007-001 Jan 4, 1991 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZOFRAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Solution 4 mg/5 mL ➤ Subscribe 2004-12-20

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
Moodys
Dow
Express Scripts
Healthtrust
Cerilliant
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.